Will RVMD draw more than $500M from the Royalty Pharma facility by December 31, 2026?

With $2.03B organic cash and ~$1.4-1.5B estimated cash OpEx for FY2026, RVMD could theoretically operate through 2026 without major Royalty Pharma draws. However, the draws may be milestone-linked rather than purely discretionary — positive RASolute 302 data could trigger milestone payments. If milestones are structured around clinical events (data readout, FDA filing), draws could be mandatory upon achievement. The $500M threshold is substantial — it represents ~29% of the remaining $1.75B commitment. Without knowing the exact milestone structure, probability is moderate.

The key uncertainty is the draw trigger structure. If draws are available at RVMD's discretion, management may choose to draw conservatively to minimize future royalty obligations. If draws are milestone-based and automatic upon clinical achievements, the amount depends on which milestones are hit in 2026. Management's stated cash runway 'into H2 2027' without Royalty Pharma draws suggests organic cash is sufficient for the near term. Drawing >$500M would primarily occur if management wants to build a larger war chest for commercial launch or if milestone triggers compel it.

If RASolute 302 reads out positively (P ~40%), RVMD would likely accelerate commercial preparations, manufacturing scale-up, and additional trial starts. This could motivate drawing aggressively from the Royalty Pharma facility to fund the commercial launch — companies often build cash buffers ahead of launch. If 302 is negative, draws would be minimal (no need for commercial cash). So P(>$500M draw) ≈ P(302 positive) × P(large draw | positive) + P(302 negative) × P(large draw | negative) ≈ 0.40 × 0.70 + 0.60 × 0.10 ≈ 0.34.

RVMD has $2.03B in organic cash. At $1.4-1.5B annual cash burn, they exit 2026 with ~$530-630M even without Royalty Pharma draws. They might not need >$500M in draws during 2026. But if they want to maintain a >$1B cash position heading into 2027 (for commercial launch and ongoing trials), they would draw to supplement. The probability depends on management's target cash floor and the milestone structure. Leaning below 30% as organic cash appears sufficient through 2026.

Management likely has a target minimum cash balance (often 2-3 quarters of operating expenses). At $400M+/quarter FY2026 GAAP OpEx, they'd want $800M-$1.2B minimum. If organic cash depletes to ~$600M by year-end, they'd need $200-600M in draws to maintain the target. The midpoint of this range approaches $400M, but exceeding $500M is plausible if management is conservative about cash positioning. Probability around 32%.

The trade-off between royalty obligations and cash adequacy favors moderate draws. Drawing $500M+ increases future royalty burden significantly. But a positive RASolute 302 readout would make the royalty payment more palatable because revenue would be expected sooner. Net: conditional on Phase III outcome, with positive data pushing draws higher. Overall probability in the low 30s.

Organic cash appears sufficient for 2026. Management will minimize draws to reduce royalty obligations. >$500M in draws unlikely unless forced by milestone triggers or aggressive commercial buildout.

The stated runway 'into H2 2027' without draws suggests organic cash is adequate near-term. But positive Phase III data could trigger both milestone draws and discretionary draws for commercial preparation. Probability around 30%.

High uncertainty about the exact draw structure. Best estimate is below 30% given organic cash adequacy and management incentive to minimize royalty obligations. But milestone-triggered draws add upside risk.